Medical Health & Life Science Research News

Market forecast for injectable drug delivery available in new report

The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

- Advertising -

Global Injectable Drug Delivery Market, By Type (Devices {Conventional Injection, Self-Injection}, Formulations {Conventional Drug Delivery, Noble Drug Delivery, Long Acting Injection Formulations}, Applications (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Oncology), Usage Pattern (Curative Care, Immunizations), Mode of Administration  (Skin, Circulatory, Organs, Central Nervous System), End User  (Hospitals & Clinics, Home Care Settings, Research Laboratories,  Pharma & Biotech Companies), Geography (North America,  Europe, Asia-Pacific, South America, Middle East Africa) – Industry Trends and Forecast to 2024

 

Global injectable drug delivery Market is expected to reach USD 789.7 billion by 2024 from USD 330.6 billion in 2016, at a CAGR of 11.5% in the forecast period 2017 to 2024. 

Report: http://databridgemarketresearch.com/toc/?dbmr=global-injectable-drug-delivery-market

Injectable Drug Delivery Market – Market Segmentation:

 

The global injectable drug delivery market is segmented on the basis of type, product type, application, usage pattern, mode of administration, end user, distribution channel, and geography.

Injectable drug delivery device market is segmented into conventional injection devices and self-injection devices. The injectable drug delivery formulation is segmented into conventional drug delivery formulation and novel drug delivery formulation.

- Advertising -

On the basis of application, the market is segmented into autoimmune disease, hormonal disorders, orphan diseases, oncology and others. The autoimmune diseases segment is further sub segmented based on indications into rheumatoid arthritis, multiple sclerosis, Crohn’s disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others.

On the basis of usage pattern, the market is segmented into curative care, immunization and other usage pattern.

On the basis of mode of administration, the market is segmented into skin, circulatory/muskoskeletal, organs and central nervous system.

On the basis of end users, the market is classified into hospitals and clinics, home healthcare, research laboratories, pharmaceutical and biotechnological companies and others.

Browse Full Report with Details TOC at databridgemarketresearch.com/reports/global-injectable-drug-delivery-market/

Based on geography, the market is segmented into five geographical regions:

 

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa

The geographical regions are further segmented into 29 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and others.

Report: http://databridgemarketresearch.com/request-a-sample/?dbmr=global-injectable-drug-delivery-market

 

Some of the major players operating in this market are

 

  1. Becton Dickinson and company
  2. Pfizer and Baxter International, Inc.,
  3. Gerresheimer AG,
  4. Schott AG,
  5. Alkermes Plc.,
  6. Eli Lilly and Company,
  7. Sandoz,
  8. Terumo Corporation,
  9. Teva Pharmaceuticals Industries Ltd.,
  10. Bespak,
  11. Antares Pharma,Elcam Medical,
  12. Haselmeier,
  13. Mylan N.V.,
  14. Novo Nordisk,
  15. Owen Mumford Ltd,
  16. Sanofi,
  17. West Pharmaceutical Services, Inc,
  18. Ypsomed Holding AG

Report: http://databridgemarketresearch.com/?dbmr=global-injectable-drug-delivery-market

Table Of Content:

 

  1. INTRODUCTION

       1.1. OVERVIEW OF THE INJECTABLE DRUG DELIVERY MARKET

       1.2. MARKET SEGMENTATION & COVERAGE

                1.2.1. CURRENCY AND PRICING

                1.2.2. LIMITATION

                1.2.3. STAKEHOLDERS

  1. RESEARCH METHODOLOGY

       2.1. KEY TAKEAWAYS

       2.2. ARRIVING AT THE INJECTABLE DRUG DELIVERY MARKET SIZE

                2.2.1. MARKET CRACKDOWN APPROACH

                2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS

                2.2.3. DATA TRIANGULATION

                2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES

                2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES

                2.2.6. PORTER’S FIVE FORCES MATRIX

       2.3. GLOBAL INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT

       2.4. ASSUMPTIONS

  1. MARKET LANDSCAPE SUMMARY
  2. PREMIUM INSIGHTS

       4.1. OVERVIEW

       4.2. INJECTABLE DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS

       4.3. MARKET OVERVIEW

                4.3.1. DRIVERS

                           4.3.1.1. RISING PREVALENCE OF CHRONIC DISEASES

                           4.3.1.2. INCRESING DEMAND OF SELF INJECTION DEVICES

                           4.3.1.3. GROWTH OF BILOGICS AND BIOSIMILARS MARKET

                           4.3.1.4. TECHNOLOGICAL ADVANCEMENTS IN DRUG DELIVERY MARKET

                4.3.2. RESTRAINTS

                4.3.3. OPPORTUNITIES

                           4.3.3.1. INCRESING DEMAND FOR GENERIC INJECTABLES

                4.3.4. THREATS

                           4.3.4.1. PRODUCT RECALLS

                           4.3.4.2. REGULATORY HURDLES

                           4.3.4.3. STABILITY OF PRODUCTS

                           4.3.4.4. STERILITY OF INJECTIONS

                           4.3.4.5. GROWING DEMAND OF OTHER DRUG DELIVERY TECHNOLOGIES

       4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES

  1. INJECTABLE DRUG DELIVERY MARKET, BY TYPE

       5.1. OVERVIEW

       5.2. INJECTABLE DRUG DELIVERY DEVICES

       5.3. INJECTABLE DRUG DELIVERY FORMULATIONS

  1. INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE

       6.1. OVERVIEW

       6.2. CONVENTIONAL INJECTION DEVICES

                6.2.1. BY MATERIAL

                           6.2.1.1. GLASS

                           6.2.1.2. PLASTIC

                6.2.2. BY PRODUCT

                           6.2.2.1. EMPTY SYRINGES

                           6.2.2.2. PREFILLED SYRINGES

                6.2.3. BY USABLITY

                           6.2.3.1. REUSABLE SYRINGES

                           6.2.3.2. DISPOSABLE SYRINGES

       6.3. SELF INJECTION DEVICES

                6.3.1. NEEDLE FREE INJECTORS

                           6.3.1.1. BY PRODUCT

                                         6.3.1.1.1. EMPTY NEEDLE FREE INJECTORS

                                         6.3.1.1.2. PREFILLED NEEDLE FREE INJECTORS

                            6.3.1.2. BY TECHNOLOGY

                                         6.3.1.2.1. JET BASED NEEDLE FREE INJECTORS

                                         6.3.1.2.2. SPRING BASED NEEDLE FREE INJECTORS

                                         6.3.1.2.3. LASER POWERED NEEDLE FREE INJECTORS

                                         6.3.1.2.4. VIBRATION BASED NEEDLE FREE INJECTORS

                           6.3.1.3. BY USABILITY

                                         6.3.1.3.1. REUSABLE NEEDLE FREE INJECTORS

                                         6.3.1.3.2. DISPOSABLE NEEDLE FREE INJECTORS

                6.3.2. AUTOINJECTORS

                           6.3.2.1. BY PRODUCT

                                         6.3.2.1.1. EMPTY AUTOINJECTORS

                                         6.3.2.1.2. PREFILLED AUTOINJECTORS

                           6.3.2.2. BY TECHNOLOGY

                                         6.3.2.2.1. AUTOMATED AUTOINJECTORS

                                         6.3.2.2.2. MANUAL AUTOINJECTORS

                           6.3.2.3. BY DESIGN

                                         6.3.2.3.1. STANDARDIZED AUTOINJECTORS

                                         6.3.2.3.2. CUSTOMIZED AUTOINJECTORS

                           6.3.2.4. BY USABILITY

                                         6.3.2.4.1. REUSABLE AUTOINJECTORS

                                         6.3.2.4.2. DISPOSABLE AUTOINJECTORS

                6.3.3. PEN INJECTORS

                           6.3.3.1. BY PRODUCT

                                         6.3.3.1.1. SINGLE CHAMBERED PEN INJECTORS

                                         6.3.3.1.2. DUAL CHAMBERED PEN INJECTORS

                           6.3.3.2. BY DESIGN

                                         6.3.3.2.1. STANDARDIZED PEN INJECTORS

                                         6.3.3.2.2. CUSTOMIZED PEN INJECTORS

                           6.3.3.3. BY USABILITY

                                         6.3.2.3.1. REUSABLE PEN INJECTORS

                                         6.3.2.3.2. DISPOSABLE PEN INJECTORS

                6.3.4. WEARABLE INJECTORS

                6.3.5. OTHER INJECTABLE DEVICES

  1. INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE

       7.1. OVERVIEW

       7.2. CONVENTIONAL DRUG DELIVERY FORMULATIONS

                7.2.1. SOLUTIONS

                7.2.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS

                7.2.3. SUSPENSIONS

                7.2.4. EMULSIONS

       7.3. NOVEL DRUG DELIVERY FORMULATIONS

                7.3.1. COLLOIDAL DISPERSIONS

                           7.3.1.1. LIPOSOMES

                           7.3.1.2. NIOSOMES

                           7.3.1.3. POLYMERIC MIXED MICELLES

                           7.3.1.4. NANOPARICLES

                                         7.3.1.4.1. NANOSUSPENSIONS

                                         7.3.1.4.2. NANOEMULSIONS/MICROEMULSIONS

                                         7.3.1.4.3. SOLID LIPID NANOPARTICLES

                7.3.2. MICROPARTICLES

                           7.3.2.1. MICROSPHERES

                           7.3.2.2. MICROCAPSULES

                7.3.3. LONG ACTING INJECTION FORMULATIONS

  1. INJECTABLE DRUG DELIVERY MARKET, BY APPLICATIONS

       8.1. OVERVIEW

       8.2. AUTOIMMUNE DISEASES

                8.2.1. RHEUMATOID ARTHRITIS

                8.2.2. MULTIPLE SCLEROSIS

                8.2.3. CHRON’S DISEASE

                8.2.4. PSORIASIS

                8.2.5. OTHER AUTOIMMUNE DISEASES

       8.3. HORMONAL DISORDERS

                8.3.1. DIABETES

                8.3.2. ANEMIA

                8.3.3. REPRODUCTIVE HEALTH DISEASE

                8.3.4. ANTITHROMBOTIC/THROMBOLYTIC THERAPY

                8.3.5. OSTEOPOROSIS

                8.3.6. GROWTH HORMONE DEFICIENCY (GHD)

       8.4. ORPHAN DISEASES

       8.5. ONCOLOGY

       8.6. OTHERS

                8.6.1. PAIN MANAGEMENT

                8.6.2. ALERGY TREATMENT

                8.6.3. AESTHETIC TREATMENTS

                8.6.4. HEPATITIS C

                8.6.5. HEMOPHILIA

  1. INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN

       9.1. OVERVIEW

       9.2. CURATIVE CARE

       9.3. IMMUNIZATIONS

       9.4. OTHER USAGE PATTERNS (BLOOD TRANSFUSION, BLOOD PRODUCTS, AND CONTRACEPTIVES)

  1. INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION

       10.1. OVERVIEW

       10.2. SKIN

       10.3. CIRCULATORY/MUSKOSKELETAL

       10.4. ORGANS

       10.5. CENTRAL NERVOUS SYSTEM

  1. INJECTABLE DRUG DELIVERY MARKET, BY END USER

       11.1. OVERVIEW

       11.2. HOSPITALS AND CLINICS

       11.3. HOME HEALTHCARE SETTINGS

       11.4. RESEARCH LABORATORIES

       11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES

       11.6. OTHER END USERS

  1. INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY

       12.1. COUNTRYWISE  INJECTABLE DRUG DELIVERY MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

                12.1.1. NORTH AMERICA

                                         12.1.1.1. U.S.

                                         12.1.1.2. CANADA

                                          12.1.1.3. MEXICO

                12.1.2. EUROPE

                                         12.1.2.1. GERMANY

                                         12.1.2.2. FRANCE

                                         12.1.2.3. U.K.

                                         12.1.2.4. ITALY

                                         12.1.2.5. SPAIN

                                         12.1.2.6. RUSSIA

                                         12.1.2.7. TURKEY

                                          12.1.2.8. BELGIUM

                                         12.1.2.9. NETHERLANDS

                                          12.1.2.7. SWITZERLAND

                                         12.1.2.8. REST OF EUROPE

                12.1.3. ASIA-PACIFIC (APAC)

                                         12.1.3.1. JAPAN

                                         12.1.3.2. CHINA

                                         12.1.3.3. SOUTH KOREA

                                         12.1.3.4. INDIA

                                         12.1.3.5. AUSTRALIA

                                         12.1.3.6. SINGAPORE

                                         12.1.3.7. THAILAND

                                         12.1.3.8. MALAYSIA

                                         12.1.3.9. INDONESIA

                                         12.1.3.10. PHILIPPINES

                                         12.1.3.11. REST OF APAC

                12.1.4. LATIN AMERICA

                                         12.1.4.1. BRAZIL

                                         12.1.4.2. REST OF LATIN AMERICA

                12.1.5. MIDDLE EAST AND AFRICA

                                         12.1.5.1. SOUTH AFRICA

                                         12.1.5.2. REST OF MIDDLE EAST AND AFRICA

       12.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

  1. INJECTABLE DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE

       13.1. GLOBAL INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS

       13.2. U.S. INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS

       13.3. EUROPE INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS

       13.4. APAC INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS

       13.5. SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS

       13.6. MIDDLE EAST AND AFRICA  INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS

       13.7. MERGERS & ACQUISITIONS

       13.8. NEW PRODUCT DEVELOPMENT & APPROVALS

       13.9. EXPANSIONS

       13.10. REGULATORY CHANGES

       13.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

  1. INJECTABLE DRUG DELIVERY MARKET, COMPANY PROFILES

       14.1. BAXTER INTERNATIONAL, INC.

                14.1.1. OVERVIEW

                14.1.2. SWOT ANALYSIS

                14.1.3. PRODUCT PORTFOLIO

                14.1.4. REVENUE ANALYSIS

                14.1.5. ANALYSTS VIEW

       14.2. BECTON, DICKINSON AND COMPANY

                14.2.1. OVERVIEW

                14.2.2. SWOT ANALYSIS

                14.2.3. PRODUCT PORTFOLIO

                14.2.4. REVENUE ANALYSIS

                14.2.5. ANALYSTS VIEW

       14.3. GERRESHEIMER, AG

                14.3.1. OVERVIEW

                14.3.2. SWOT ANALYSIS

                14.3.3. PRODUCT PORTFOLIO

                14.3.4. REVENUE ANALYSIS

                14.3.5. ANALYST VIEW

       14.4. PFIZER, INC.

                14.4.1. OVERVIEW

                14.4.2. SWOT ANALYSIS

                14.4.3. PRODUCT PORTFOLIO

                14.4.4. REVENUE ANALYSIS

                14.4.5. ANALYSTS VIEW

       14.5. SCHOTT AG

                14.5.1. OVERVIEW

                14.5.2. SWOT ANALYSIS

                14.5.3. PRODUCT PORTFOLIO

                14.5.4. REVENUE ANALYSIS

                14.5.5. ANALYSTS VIEW

       14.6. ALKERMES PLC

                14.6.1. OVERVIEW

                14.6.2. SWOT ANALYSIS

                14.6.3. PRODUCT PORTFOLIO

                14.6.4. REVENUE ANALYSIS

                14.6.5. ANALYSTS VIEW

       14.7. ELI LILLY AND COMPANY

                14.7.1. OVERVIEW

                14.7.2. SWOT ANALYSIS

                14.7.3. PRODUCT PORTFOLIO

                14.7.4. REVENUE ANALYSIS

                14.7.5. ANALYSTS VIEW

       14.8. SANDOZ

                14.8.1. OVERVIEW

                14.8.2. SWOT ANALYSIS

                14.8.3. PRODUCT PORTFOLIO

                14.8.4. REVENUE ANALYSIS

                14.8.5. ANALYSTS VIEW

       14.9. TERUMO CORPORATION

                14.9.1. OVERVIEW

                14.9.2. SWOT ANALYSIS

                14.9.3. PRODUCT PORTFOLIO

                14.9.4. REVENUE ANALYSIS

                14.9.5. ANALYSTS VIEW

       14.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.

                14.10.1. OVERVIEW

                14.10.2. SWOT ANALYSIS

                14.10.3. PRODUCT PORTFOLIO

                14.10.4. REVENUE ANALYSIS

                14.10.5. ANALYSTS VIEW

  1. APPENDIX

       15.1. RELATED REPORTS

       15.2. CUSTOMIZABLE OPTIONS

       15.3. SOURCE SHEET

       15.4. BIBLIOGRAPHY

  1. ABOUT DATA BRIDGE MARKET RESEARCH

 

News From

Data Bridge Market ResearchData Bridge Market Research
Category: Market Research Publishers and RetailersCompany profile: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wi ...